Abstract
Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial. The primary endpoint was radiographic response rate. Secondary endpoints included progression-free survival and correlation of molecular profiles with treatment response. 36% of patients had stable disease and 14% a partial response; however, responses were not durable and only one patient was progression-free at six months. Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects. EGFR and PTEN status did not clearly predict response to treatment.
Publication types
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / metabolism
-
Brain Neoplasms / mortality
-
Disease-Free Survival
-
ErbB Receptors / biosynthesis
-
Everolimus
-
Female
-
Gefitinib
-
Glioblastoma / drug therapy*
-
Glioblastoma / metabolism
-
Glioblastoma / mortality
-
Humans
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
PTEN Phosphohydrolase / biosynthesis
-
Pilot Projects
-
Proto-Oncogene Proteins c-akt
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Sirolimus / administration & dosage
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives
Substances
-
Quinazolines
-
Everolimus
-
ErbB Receptors
-
Proto-Oncogene Proteins c-akt
-
PTEN Phosphohydrolase
-
PTEN protein, human
-
Gefitinib
-
Sirolimus